Sergei Syrbu

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais et al. · Journal of Clinical Oncology · 2014 · 399 citations · Full text

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

Brian K. Link, Matthew J. Maurer, Grzegorz S. Nowakowski et al. · Journal of Clinical Oncology · 2013 · 326 citations · Full text

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Matthew J. Maurer, Emmanuel Bachy, Hervé Ghesquières et al. · American Journal of Hematology · 2016 · 219 citations · Full text

Lymphoid Neoplasia, Cancer Epidemiology, Medicine +14

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials

Matthew J. Maurer, Hervé Ghesquières, Brian K. Link et al. · Journal of Clinical Oncology · 2018 · 132 citations

Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma

Matthew J. Maurer, Ivana N. Micallef, James R. Cerhan et al. · Journal of Clinical Oncology · 2011 · 83 citations · Full text